Dr. Scott Whitcup is the Founder and CEO of Akrivista, a company focused on developing novel treatments in ophthalmology. Previously, he was EVP, R&D and Chief Scientific Officer at Allergan with experience running a large R&D organization with > 2500 employees and an annual budget of >$1B, and participated in many commercial launches. He has R&D expertise in ophthalmology, CNS, urology, dermatology, medical aesthetics, anti-infectives, and obesity. He has been extensively involved in business development, and has Board experience on both private and public companies. Dr. Whitcup has served on the Board of Semnur Pharmaceuticals since 2013. He was a Director at Avanir Pharmaceuticals (2005– 2014), serving as Chair, Science Committee, and Member, Corporate Governance Committee. Avanir was acquired for $3.5B by Otsuka in January 2015.
A Director on Questcor Pharmaceuticals’ Board (2012– 2014), Dr. Whitcup was Chair, Compliance and Science Committees. Questcor was acquired for $5.6B by Mallinckrodt in 2014. Dr. Whitcup also serves as a special advisor to Vivo Ventures. He joined Allergan in 2000. As EVP, R&D and CSO, he was also on Allergan’s Executive Committee and Head, R&D Development and Portfolio Committees. He led Discovery Research, Clinical Development of pharmaceutical products and medical devices worldwide, global medical affairs, and biologics manufacturing research. He obtained over 20 major product approvals in multiple therapeutic areas including Botox®, Restasis®, Lumigan®, Latisse®, and Juvederm Voluma® XC. He ran the technology assessment group and managed acquisitions and integrations. He has over 150 patents. Before, Dr. Whitcup worked in leadership positions at the National Eye Institute at NIH. He has a BA from Cornell University and an MD from Cornell’s Medical College; has completed Internal Medicine (UCLA Medical Center) and Ophthalmology (Harvard Medical School) residencies, and a fellowship in Uveitis/Ocular Immunology at the NEI.